{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:56.862600+00:00","company":{"ticker":"BIIB","cik":875045,"company_name":"BIOGEN INC."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"debt_financing","fact_key":"0c4a4d81a52bdc6755d90b01583b1d93ad88da2a","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2026-05-14T12:31:16+00:00","payload":{"counterparty":"U.S. Bank National Association","effective_date":"2026-05-13","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"Term SOFR plus an applicable margin ranging from 0.750% to 1.000%","item_codes_triggered":["2.03"],"maturity_text":"May 12, 2028","principal_text":"$1 billion"},"claim":"BIOGEN INC. incurred term loan of $1 billion with U.S. Bank National Association at Term SOFR plus an applicable margin ranging from 0.750% to 1.000% maturing May 12, 2028.","evidence_excerpt":"The Credit Agreement provides for unsecured term loan facilities in an aggregate principal amount of $2 billion (the “Term Facilities”), comprised of a $1 billion 364-day tranche (“Tranche A”) and a $1 billion two-year tranche (“Tranche B”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-222908","anchor_url":"https://secwatch.observer/filing/0001193125-26-222908#claim-0c4a4d81a52bdc6755d90b01583b1d93ad88da2a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/0001193125-26-222908-index.htm"},{"fact_type":"debt_financing","fact_key":"5a20f7267687e82e1352e1117260725b45c29515","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2026-05-14T12:31:16+00:00","payload":{"counterparty":"U.S. Bank National Association","effective_date":"2026-05-13","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"Term SOFR plus an applicable margin of 0.750% or Base Rate plus an applicable ma","item_codes_triggered":["2.03"],"maturity_text":"May 12, 2027","principal_text":"$1 billion"},"claim":"BIOGEN INC. incurred term loan of $1 billion with U.S. Bank National Association at Term SOFR plus an applicable margin of 0.750% or Base Rate plus an applicable ma maturing May 12, 2027.","evidence_excerpt":"The Credit Agreement provides for unsecured term loan facilities in an aggregate principal amount of $2 billion (the “Term Facilities”), comprised of a $1 billion 364-day tranche (“Tranche A”) and a $1 billion two-year tranche (“Tranche B”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-222908","anchor_url":"https://secwatch.observer/filing/0001193125-26-222908#claim-5a20f7267687e82e1352e1117260725b45c29515","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/0001193125-26-222908-index.htm"},{"fact_type":"ma_transaction","fact_key":"a26cc7d92fce54e377333361a5c418a7be60e2b7","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2026-05-14T12:31:16+00:00","payload":{"action":"acquisition","closing_date":"2026-05-14","consideration_text":"Cash Amount of $41.00 per Share plus one CVR per Share representing contingent cash payments of up to an aggregate of $4.00 per Share","counterparty":"Apellis Pharmaceuticals, Inc.","effective_date":"2026-05-14","item_codes_triggered":["2.01"]},"claim":"BIOGEN INC. completed an acquisition involving Apellis Pharmaceuticals, Inc. for Cash Amount of $41.00 per Share plus one CVR per Share representing contingent cash payments of up to an aggregate of $4.00 per Share (closed 2026-05-14).","evidence_excerpt":"CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-222908","anchor_url":"https://secwatch.observer/filing/0001193125-26-222908#claim-a26cc7d92fce54e377333361a5c418a7be60e2b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/0001193125-26-222908-index.htm"},{"fact_type":"earnings_release","fact_key":"9626167b866b844e91eeb357d17a94d78c7d4e42","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":"GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":"$2,478"},"claim":"BIOGEN INC. reported the first quarter ended March 31, 2026 results: revenue $2,478, EPS GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57. Guidance raised.","evidence_excerpt":"and reported important positive new data that reinforce our confidence in the late‐stage pipeline.\" Financial Highlights Q1 '26 Q1 '25 △ r (CC * ) Total Revenue (in millions) $2,478 $2,431 2% (2)% GAAP diluted EPS $2.15 $1.64 31% N/A Non-GAAP diluted EPS $3.57 $3.02 18% N/A Note: Percent changes represented as favorable/(unfavorable) versus the prior year","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000875045-26-000042","anchor_url":"https://secwatch.observer/filing/0000875045-26-000042#claim-9626167b866b844e91eeb357d17a94d78c7d4e42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/0000875045-26-000042-index.htm"},{"fact_type":"earnings_release","fact_key":"fe3f204dc365828a89af38a6a858ef4472c2e7ff","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2026-04-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter of 2026","report_date":"2026-04-06","result_type":"preliminary_results","revenue_text":null},"claim":"BIOGEN INC. reported preliminary financial results for the first quarter of 2026.","evidence_excerpt":"Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0000875045-26-000039","anchor_url":"https://secwatch.observer/filing/0000875045-26-000039#claim-fe3f204dc365828a89af38a6a858ef4472c2e7ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/0000875045-26-000039-index.htm"},{"fact_type":"material_agreement","fact_key":"4a09f683f3e36c6f163ff9173d8eece720a1b007","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"Apellis Pharmaceuticals, Inc.","effective_date":"2026-03-31","item_codes_triggered":["1.01"],"value_text":"$41.00 per share of Apellis Common Stock"},"claim":"BIOGEN INC. entered into Merger Agreement with Apellis Pharmaceuticals, Inc. valued at $41.00 per share of Apellis Common Stock (effective 2026-03-31).","evidence_excerpt":"On March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-134889","anchor_url":"https://secwatch.observer/filing/0001193125-26-134889#claim-4a09f683f3e36c6f163ff9173d8eece720a1b007","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312526134889/0001193125-26-134889-index.htm"},{"fact_type":"executive_change","fact_key":"852ced4184","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2025-01-15T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-03-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Robin Kramer","successor_named":true},"claim":"Michael McDonnell departed as Chief Financial Officer at BIOGEN INC..","evidence_excerpt":"Mr. McDonnell will retire on March 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-006578","anchor_url":"https://secwatch.observer/filing/0001193125-25-006578#claim-852ced4184","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312525006578/0001193125-25-006578-index.htm"},{"fact_type":"executive_change","fact_key":"2463e4e8c9","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2025-01-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Michael McDonnell","successor_named":true},"claim":"Robin Kramer was appointed as Chief Financial Officer at BIOGEN INC..","evidence_excerpt":"As previously announced, Ms. Kramer has been appointed the Company’s Chief Financial Officer, effective upon the retirement of Michael McDonnell, the Company’s current Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-006578","anchor_url":"https://secwatch.observer/filing/0001193125-25-006578#claim-2463e4e8c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312525006578/0001193125-25-006578-index.htm"},{"fact_type":"executive_change","fact_key":"65011df29d","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2025-01-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-01","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":"Robin Kramer","successor_named":true},"claim":"Sean Godbout was appointed as Chief Accounting Officer at BIOGEN INC..","evidence_excerpt":"On January 13, 2025, Biogen Inc. (the “Company”) appointed Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller and designated Mr. Godbout as the Company’s principal accounting officer, in each case effective as of March 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-006578","anchor_url":"https://secwatch.observer/filing/0001193125-25-006578#claim-65011df29d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312525006578/0001193125-25-006578-index.htm"},{"fact_type":"executive_change","fact_key":"f97301c3e0","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-28","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Robin Kramer was appointed as Chief Financial Officer at BIOGEN INC..","evidence_excerpt":"Robin Kramer, the Company’s Chief Accounting Officer and Head of Global Business Services and Treasury has been appointed Chief Financial Officer effective upon Mr. McDonnell’s retirement.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-247628","anchor_url":"https://secwatch.observer/filing/0001193125-24-247628#claim-f97301c3e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312524247628/0001193125-24-247628-index.htm"},{"fact_type":"executive_change","fact_key":"a46f0ad745","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-02-28","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Robin Kramer","successor_named":true},"claim":"Michael McDonnell departed as Chief Financial Officer at BIOGEN INC..","evidence_excerpt":"On October 28, 2024, Michael McDonnell, Chief Financial Officer of Biogen Inc. (the “Company”) notified the Company that he will retire from the Company effective February 28, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-247628","anchor_url":"https://secwatch.observer/filing/0001193125-24-247628#claim-a46f0ad745","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312524247628/0001193125-24-247628-index.htm"},{"fact_type":"executive_change","fact_key":"0b2e3e31c8","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2024-09-12T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sir Menelas (Mene) Pangalos was elected as director at BIOGEN INC..","evidence_excerpt":"On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-217633","anchor_url":"https://secwatch.observer/filing/0001193125-24-217633#claim-0b2e3e31c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312524217633/0001193125-24-217633-index.htm"},{"fact_type":"executive_change","fact_key":"b322462363","cik":875045,"ticker":"BIIB","company_name":"BIOGEN INC.","filed_at":"2024-09-12T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lloyd B. Minor was elected as director at BIOGEN INC..","evidence_excerpt":"On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-217633","anchor_url":"https://secwatch.observer/filing/0001193125-24-217633#claim-b322462363","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312524217633/0001193125-24-217633-index.htm"}]}